Abstract:Background:In the pathogenesis of Alzheimer's disease (AD), microglia play an increasingly important role. Molecular imaging of neuroinflammatory targeting microglia activation and the high expression of 18-kDa translocator protein (TSPO) has become a hot topic of research in recent years. Dynamic monitoring neuroinflammation is crucial for discovering the best time point of anti-inflammatory therapy. Motivated by this, Positron emission tomography (PET) imaging in an APP/PS1 mouse model of AD, using(18)F-labeled DPA-714 to monitor microglia activation and neuroinflammation, were performed in this paper. Methods:We prepared [F-18]DPA714 and tested the biological characteristics of the molecular probe in normal mice. To obtain a higher radiochemical yield, we improved the [F-18]-fluorination conditions in the precursor dosage, reaction temperature, and synthesis time. We performed [F-18]DPA714 PET scanning on APP/PS1 mice at 6-7, 9-10, 12-13, and 15-16 months of age, respectively. The same experiments were conducted in Wild-type (Wt) mice as a control. Referring to the [F-18]DPA714 concentrated situation in the brain, we performed blocking experiments with PK11195 (1 mg/kg) in 12-13-months-old APP/PS1 mice to confirm the specificity of [F-18]DPA714 for TSPO in the APP/PS1 mice. Reconstructed brain PET images, fused with the Magnetic Resonance Imaging (MRI) template atlas, and the volumes of interests (VOIs) of the hippocampus and cortex were determined. The distribution of [F-18]DPA714 in the brain tissues of 15-16-months-old APP/PS1 and Wt mice were studied by immunofluorescence staining. Results:Through the reaction of(18)F, with 2 mg precursor dissolved in 300 ul acetonitrile at 105 degrees C for 10 min, we obtained the optimal radiochemical yield of 42.3 +/- 5.1% (non-decay correction). Quantitative analysis of brain PET images showed that the [F-18]DPA714 uptake in the cortex and hippocampus of 12-13-months-old APP/PS1 mice was higher than that of the control mice of the same age (cortex/muscle: 2.77 +/- 0.13 vs. 1.93 +/- 0.32,p= 0.0014; hippocampus/muscle: 3.33 +/- 0.10 vs. 2.10 +/- 0.35,p= 0.0008). The same significant difference was found between 15- and 16-months-old APP/PS1 mice (cortex/muscle: 2.64 +/- 0.14 vs. 1.86 +/- 0.52, p=0.0159; hippocampus/muscle: 2.89 +/- 0.53 vs. 1.77 +/- 0.48,p= 0.0050). Immunofluorescence staining showed that the activation of microglia and the level of TSPO expression in the cortex and hippocampus of APP/PS1 mice were significantly higher than Wt mice. Conclusion:[F-18]DPA714, a molecular probe for targeting TSPO, showed great potential in monitoring microglia activation and neuroinflammation, which can be helpful in discovering the best time point for anti-inflammatory therapy in AD.

[ 18 F]-PM-PBB3-PET Tau Imaging in Alzheimer’s Dementia and PSP

Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation.

Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer's Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

International Consensus on the Use of Tau PET Imaging Agent 18F-Flortaucipir in Alzheimer's Disease.

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

In vitro evaluation of [3H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies

Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease

Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and β-amyloid deposition quantification

[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer's disease

Novel β-amyloid PET Imaging Study of [ 18 F]92 in Patients with Cognitive Decline

Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort

18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy

Synthesis and Preclinical Evaluation of 2-(4-[ 18 F]Fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([ 18 F]FPND-4): An Aza-Fused Tricyclic Derivative as Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging

18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism

Synthesis and Radiolabelling of A Radiofluorinated Pet Imaging Probe Based on Pib and Thk523

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

Pet Imaging For Dynamically Monitoring Neuroinflammation In App/Ps1 Mouse Model Using [F-18]Dpa714

Biological Characteristics of [ 18 F]-THK523 for Tau Imaging

Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer's Disease